Evaluation on 16-years immune efficacy of two kinds of hepatitis B vaccines among newborns in Huangpu District of Shanghai

Wen MU,Jian-jun ZHOU,Fei SU,Xuan-yi WANG,Ling YAN
DOI: https://doi.org/10.13329/j.cnki.zyyjk.2017.0233
2017-01-01
Abstract:[Objective] To evaluate the long-term immune efficacy of plasma-derived hepatitis B vaccine (PDV) and domestic yeast-derived recombinant hepatitis B vaccine (YDV).[Methods] The subjects born in 1986 immunized with PDV and subjects bonn in 1997 immunized with YDV in Huangpu District of Shanghai were followed up every other year.The blood samples were collected to test HBsAg,Anti-HBs and Anti-HBc,which were compared to the background results from a cross-sectional survey of hepatitis B virus in 1984-1985 to calculate protecting rate,and an added survey on acute hepatitis B was carried out.[Results] In the past 16 years,the positive rates of HBsAg,Anti-HBs and Anti-HBc were respectively 0.47%,28.20% and 1.18% in PDV group,and they were respectively 0.94%,12.85% and 0.63% in YDV group.There were no significant increases in the positive rate of HBsAg and Anti-HBc in both groups,while the positive rates of Anti-HBs in two groups decreased significantly (the positive rate decreased from 89.72% to 28.20% in PDV group and decreased from 93.72% to 12.85% in YDV group).The main difference between these two vaccines was the positive rate of Anti-HBs in YDV group was lower than that in PDV group between 5th and 16th years after vaccination,and the former (decreased by 80.87%) dropped more dramatically than the latter (decreased by 61.52%).[Conclusion] The antibody levels of two vaccines decrease year by year,and YDV drops more dramatically than PDV,but there is no difference in protection effect against hepatitis B between them.It is indicated that the 16-years immune efficacy of PDV and YDV is satisfactory,and there is no need for a booster dose
What problem does this paper attempt to address?